AgomAb Therapeutics NV

AgomAb Therapeutics NV について当サイトが保有する最新の四半期

企業自身の 6-K から。

経営陣の発言

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

AgomAb Therapeutics NV の事業内容

Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

発表資料の末尾に記載された、企業自身による説明です。